Compare TJX Companies Inc (TJX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs GeneDx Holdings Corp — how do they compare? TJX Companies Inc trades at $154.6 (market cap $172.00B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: TJX Companies Inc is far larger — about 95.6× GeneDx Holdings Corp's market cap, and TJX Companies Inc pays a 1.23% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TJX | WGS | |
|---|---|---|
Market Cap | $172.00B | $1.80B |
Sector | Consumer Cyclical | Technology |
52-Week High | $168.41 | $167.51 |
52-Week Low | $124.53 | $34.51 |
Enterprise Value | $180.60B | $1.80B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TJX trades at $155.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported revenue of $56.36 billion in 2025 with a net income margin of 9.4%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights TJX as a beneficiary of shifting retail trends and economic uncertainty.
The outlook for TJX remains positive, driven by earnings growth, international expansion, and strong analyst support with a consensus price target of $181.80. Key risks include competitive pressures in discount retail and sensitivity to consumer spending fluctuations, but the company's robust cash flow and dividend payments provide stability.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
